TR-1 notification of major interest in shares

The full announcement is available here

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

US FDA approval for Quo-Test analyser

EKF Diagnostics announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

Update on McKesson US distribution agreement for DiaSpect Tm

EKF announces the full launch of the McKesson Consult^® Hb analyzer in the US in February.

Trading update

EKF Diagnostics provides shareholders with the following update on current trading.

Update regarding planned change of nominated adviser

EKF Diagnostics Holdings plc announces that, further to the announcement on 1 November regarding its planned appointment of a new nominated adviser following the admission of Renalytix AI PLC (“RenalytixAI”) to trading on AIM, the boards of EKF and RenalytixAI have now agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.

PDMR dealing

EKF Diagnostics announces that on 19 December 2018, the Company was notified by Mike Salter (President, Americas) that he has today purchased 125,000 ordinary shares.